Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

trialsTrialActive

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

A phase 2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by R-Pharm International, LLC, active and no longer recruiting.

Overview Connected5

Overview

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 2 interventional study registered as NCT07553988 by R-Pharm International, LLC, with 120 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05-14. Interventions recorded: RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mg, Abiraterone, Prednisolone. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

Setting

A Phase II, Open-label, Randomized, Comparative Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Phase

Phase 2

Sponsor

R-Pharm International, LLC

Registry

Started

2024-10-24

Enrolled

120 enrolled

Connected

Similar pages

Trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.
Trial
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Trial
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Trial
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.
Trial
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Trial
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Trial
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.
Trial
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.

cancers

Metastatic castration-resistant prostate cancer Prostate cancer

drugs

ApprovedSmall-molecule CYP17A1 inhibitor

Abiraterone acetate · Zytiga (generic)

ApprovedGlucocorticoid

Prednisone · Deltasone (historic) / Rayos

companies

Evidence strength30/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
120 enrolled+10
No structured primary endpoint0
Result: active0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 1,018 registry trials to cancer subtype pages by dri… · diff · file

Sources & links

ClinicalTrials.gov NCT07553988

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Prostate cancer
Metastatic castration-resistant prostate cancer

Products

Abiraterone acetate
Prednisone

Companies

R-Pharm

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct07553988/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct07553988.

WebMCP tools registered on this page: onco_search, onco_get_entity.